A Phase 3 drug are worth $1.1 Billion and it costs $154 Million to get to that point. $1.1 Billion give Revise market cap five dollar. For Covid-19 probably valued a lot higher. Great news only a few drug treatment makes it to phase 3 covid-19 trials. Furthermore, I don't see there is any drug that has the safety and low side effects that Bucillamine has on going trials. How to calculate the value of drugs and biotech companies https://www.baybridgebio.com/drug_valuation.html So much upside here. I really believe its possible to see 500% green day on the right news for this stock. I firmly believe we will be trading dollars in the coming weeks, and double digit dollars as the trial progresses. CYDY have the market value sixteen time higher than us, NIO hundred time higher than us and they not yet on phase 3 trial.
NIO 18.50 15.3 Billion Market Cap Phase 1 CV-19
CYDY 3.44 1.9 Billion Market Cap Phase 2 CV-19
VXRT 6.23 680 million market Cap Preclinical CV-19
News 
Market Data 
Discover 
